0
Introduction to the Acquisition In one of the most significant moves within the pharmaceutical sector in recent years, Novo Holdings has announced the acquisition of Catalent for a substantial $16.5 billion. This acquisition represents a strategic intervention by Novo Holdings, aimed at enhancing its portfolio and consolidating its position in the rapidly evolving biotechnology landscape.…